New heart valve offers hope for High-Risk patients
NCT ID NCT06167213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new heart valve (SAPIEN X4) in 125 people with mitral valve disease who are too high-risk for open-heart surgery. The valve is placed using a thin tube through a blood vessel, avoiding major surgery. The goal is to see if the valve is safe and improves heart function and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITRAL REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New heart valve device could spare High-Risk patients from Open-Heart surgery
- First-in-Human trial aims to offer new hope for patients with leaky heart valves who Can't have surgery
- Wireless sensor could help doctors Fine-Tune heart failure treatment in real time
- New heart valve design aims to simplify replacements and cut risks
- Tiny device could fix leaky heart valves without cutting chest open
- New study observes Non-Surgery heart valve patients to guide better care